GeoVax Labs Past Earnings Performance
Past criteria checks 0/6
GeoVax Labs's earnings have been declining at an average annual rate of -49.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 42.8% per year.
Key information
-49.3%
Earnings growth rate
56.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -42.8% |
Return on equity | -450.6% |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully
Sep 08GeoVax: Possible Vaccine Advancements In 2 Big Indications
Aug 08GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine
Jul 28Companies Like GeoVax Labs (NASDAQ:GOVX) Could Be Quite Risky
May 24GeoVax: A Legitimate COVID-19 Phase 2 Vaccine Candidate Trading At Only A $25 Million Valuation
Dec 27We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Nov 27GeoVax: Expands Immuno-Oncology Pipeline With Clinical-Stage Program
Oct 03We Think GeoVax Labs (NASDAQ:GOVX) Can Afford To Drive Business Growth
Aug 14Did Business Growth Power GeoVax Labs' (NASDAQ:GOVX) Share Price Gain of 111%?
Feb 18GeoVax soars on NIAID grant for COVID-19 vaccine candidate
Jan 11Revenue & Expenses BreakdownBeta
How GeoVax Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -26 | 6 | 20 |
30 Sep 23 | 0 | -24 | 6 | 0 |
30 Jun 23 | 0 | -19 | 6 | 0 |
31 Mar 23 | 0 | -16 | 5 | 0 |
31 Dec 22 | 0 | -14 | 5 | 9 |
30 Sep 22 | 0 | -22 | 4 | 0 |
30 Jun 22 | 0 | -20 | 4 | 0 |
31 Mar 22 | 0 | -19 | 4 | 0 |
31 Dec 21 | 0 | -19 | 4 | 0 |
30 Sep 21 | 0 | -6 | 3 | 0 |
30 Jun 21 | 1 | -5 | 3 | 0 |
31 Mar 21 | 1 | -4 | 3 | 0 |
31 Dec 20 | 2 | -3 | 2 | 0 |
30 Sep 20 | 2 | -2 | 2 | 0 |
30 Jun 20 | 2 | -2 | 2 | 0 |
31 Mar 20 | 2 | -2 | 2 | 0 |
31 Dec 19 | 1 | -2 | 2 | 0 |
30 Sep 19 | 1 | -2 | 2 | 0 |
30 Jun 19 | 1 | -3 | 2 | 0 |
31 Mar 19 | 1 | -3 | 2 | 0 |
31 Dec 18 | 1 | -3 | 2 | 0 |
30 Sep 18 | 1 | -2 | 1 | 0 |
30 Jun 18 | 1 | -2 | 1 | 0 |
31 Mar 18 | 1 | -2 | 1 | 0 |
31 Dec 17 | 1 | -2 | 1 | 0 |
30 Sep 17 | 1 | -3 | 2 | 0 |
30 Jun 17 | 1 | -2 | 2 | 0 |
31 Mar 17 | 1 | -3 | 2 | 0 |
31 Dec 16 | 1 | -3 | 2 | 0 |
30 Sep 16 | 1 | -3 | 2 | 0 |
30 Jun 16 | 0 | -3 | 2 | 0 |
31 Mar 16 | 0 | -3 | 2 | 0 |
31 Dec 15 | 0 | -3 | 1 | 0 |
30 Sep 15 | 0 | -3 | 2 | 0 |
30 Jun 15 | 1 | -3 | 2 | 0 |
31 Mar 15 | 1 | -3 | 2 | 0 |
31 Dec 14 | 1 | -3 | 2 | 0 |
30 Sep 14 | 1 | -3 | 2 | 0 |
30 Jun 14 | 2 | -2 | 1 | 0 |
31 Mar 14 | 2 | -2 | 2 | 0 |
31 Dec 13 | 2 | -2 | 2 | 0 |
30 Sep 13 | 3 | -2 | 2 | 0 |
30 Jun 13 | 2 | -2 | 2 | 0 |
Quality Earnings: GOVX is currently unprofitable.
Growing Profit Margin: GOVX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GOVX is unprofitable, and losses have increased over the past 5 years at a rate of 49.3% per year.
Accelerating Growth: Unable to compare GOVX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GOVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: GOVX has a negative Return on Equity (-450.55%), as it is currently unprofitable.